NVCT

Nuvectis Pharma, Inc. NVCT

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$188.95M total
TANG CAPITAL MANAGEMENT LLC
$28.50MNew
BlackRock, Inc.
$18.41M+31.0%
PERCEPTIVE ADVISORS LLC
$18.39MNew
Soleus Capital Management, L.P.
$18.39MNew
VANGUARD CAPITAL MANAGEMENT LLC
$16.04M+32.2%
IRIDIAN ASSET MANAGEMENT LLC/CT
$14.29M+19.2%
GEODE CAPITAL MANAGEMENT, LLC
$7.95M+12.5%
Occam Crest Management LP
$7.39M-12.3%
SPHERA FUNDS MANAGEMENT LTD.
$7.04MNew
BALDWIN WEALTH PARTNERS LLC/MA
$7.03M+0.9%
Alyeska Investment Group, L.P.
$5.06MNew
STATE STREET CORP
$4.56M+49.1%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$4.00M+106.4%
Avidity Partners Management LP
$3.68MNew
NORTHERN TRUST CORP
$2.70M+18.1%
VANGUARD FIDUCIARY TRUST CO
$2.35M+11.1%
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.18M+28.4%
CITADEL ADVISORS LLC
$2.12M+47.3%
Kalehua Capital Management LLC
$1.84MNew
OPPENHEIMER & CO INC
$1.35M0.0%
UBS Group AG
$1.27M+79.4%
FORBES J M & CO LLP
$1.09M0.0%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$1.05M+15.1%
CIBC Bancorp USA Inc.
$917.7K+161.7%
Informed Momentum Co LLC
$867.4KNew
See all 83 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/NVCT

Earnings Per Share

13fpro.ai/company/NVCT

Loading ratio trend…

NVCT insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Nuvectis Pharma, Inc. (NVCT): stock profile, AI score and financials

Nuvectis Pharma, Inc. (NVCT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. NVCT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of NVCT by reported 13-F value include TANG CAPITAL MANAGEMENT, BlackRock, PERCEPTIVE ADVISORS, based on the most recent SEC filings. NVCT trades on the Nasdaq exchange and files with the SEC under CIK 1875558. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nuvectis Pharma, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1875558 →